
Biomed Industries Presents Breakthrough Phase 2 Results of NA-931, an Oral Quadruple Agonist for Obesity , at ADA 2025
Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 SAN JOSE, CA, UNITED STATES, June 23, 2025 /EINPresswire.com/ -- Biomed Industries, Inc. ( …